Navigation Links
Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates

HUNTSVILLE, Ala., July 31, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has entered into a research agreement with the Scripps Research Institute for development of polymer-antibody drug conjugates (Polymer-ADCs). The nature of the agreement and the financial terms were not disclosed.

"Antibody drug conjugates represent one of the most exciting areas of drug development in oncology," according to Dr. Randall Moreadith, President and Chief Executive Officer of Serina Therapeutics, Inc. "The ability to target antibodies that are "pay-loaded" with a potent cytotoxic agent has started to produce the first generation of approved antibody drug conjugates. Our polymer technology platform is uniquely suited to advance this field. We are very excited about working with some of the premier antibody scientists in the world at the Scripps Research Institute to develop next-generation ADCs."

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit

About Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, TSRI has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where it's renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see

CONTACT: Randall Moreadith, 256-327-0470,

SOURCE Serina Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
2. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
3. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
4. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
5. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
6. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
7. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
8. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
9. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
10. Cell Therapeutics to Report Second Quarter Financial Results after Market on July 31, 2013
11. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... MELVILLE, N.Y. , Nov. 25, 2015  Henry ... products and services to office-based dental, medical and animal ... Dental (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion ... industry,s broadest array of open solutions designed to help ... Click here for a schedule of ...
Breaking Medicine Technology:
(Date:11/25/2015)... Ill. (PRWEB) , ... November 25, 2015 , ... ... and potentially more aggressive than those found on mammography, according to a study ... findings of additional cancers not seen on mammography may necessitate a change in ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... United States District Court of Connecticut on behalf of a home health care worker ... all current or former home health care workers employed by Humana, Inc., Humana at ...
Breaking Medicine News(10 mins):